Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDK2 | P24941 | 11/20 | 0.71 |
| ▸ | CDK1 | P06493 | 5/20 | 0.71 |
| ▸ | CCNB1 | P14635 | 2/20 | 0.71 |
| ▸ | CCNE1 | P24864 | 2/20 | 0.71 |
| ▸ | ADORA2A | P29274 | 2/20 | 0.58 |
| ▸ | ADORA1 | P30542 | 2/20 | 0.58 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.58 |
| ▸ | PI4KA | P42356 | 1/20 | 0.58 |
| ▸ | PI4K2B | Q8TCG2 | 1/20 | 0.58 |
| ▸ | PI4K2A | Q9BTU6 | 1/20 | 0.58 |
| ▸ | PI4KB | Q9UBF8 | 1/20 | 0.58 |
| ▸ | CCNA2 | P20248 | 8/20 | 0.53 |
| ▸ | CCNA1 | P78396 | 8/20 | 0.53 |
| ▸ | CDK5 | Q00535 | 8/20 | 0.53 |
| ▸ | CDK5R1 | Q15078 | 8/20 | 0.53 |
| ▸ | DYRK1A | Q13627 | 7/20 | 0.53 |
| ▸ | PDE8A | O60658 | 3/20 | 0.51 |
| ▸ | PDE2A | O00408 | 1/20 | 0.51 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.51 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24434593 | 0.89 | CDK1 (0.61) | CDK2CDK1CCNB1CCNE1ADORA2A | |
| SCHEMBL24835574 | 0.87 | CDK1 (0.59) | CDK2CDK1CCNB1CCNE1ADORA2A | |
| SCHEMBL22402774 | 0.84 | ADORA2A (0.62) | CDK2CDK1CCNB1CCNE1ADORA2A | |
| SCHEMBL23619350 | 0.84 | CDK1 (0.56) | CDK2CDK1CCNB1CCNE1ADORA2A | |
| SCHEMBL29611365 | 0.83 | CDK1 (1.00) | CDK2CDK1CCNB1CCNE1ADORA2A | |
| SCHEMBL756644 | 0.83 | CDK1 (1.00) | CDK2CDK1CCNB1CCNE1ADORA2A | |
| SCHEMBL29426182 | 0.83 | CDK2 (0.56) | CDK2CDK1CCNB1CCNE1ADORA2A | |
| SCHEMBL539356 | 0.83 | CDK2 (0.56) | CDK2CDK1CCNB1CCNE1ADORA2A | |
| SCHEMBL26349114 | 0.83 | CDK1 (0.58) | CDK2CDK1CCNB1CCNE1ADORA2A | |
| SCHEMBL27748107 | 0.82 | CDK1 (0.54) | CDK2CDK1CCNB1CCNE1ADORA2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 75 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240066047-A1 | ANTIBODY-DRUG CONJUGATES COMPRISING A CYCLIC DINUCLEOTIDE | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2024-02-29 | — | — | US | disclosed |
| US-11840551-B2 | Compositions and methods of modulating the immune response by activating alpha protein kinase 1 | SHANGHAI YAO YUAN BIOTECHNOLOGY CO., LTD. (CN) | 2023-12-12 | — | — | US | disclosed |
| US-11840551-B2 | Compositions and methods of modulating the immune response by activating alpha protein kinase 1 | SHANGHAI YAO YUAN BIOTECHNOLOGY CO., LTD. (CN) | 2023-12-12 | — | — | US | disclosed |
| US-20230374058-A1 | COMPOUNDS AND METHODS FOR TREATING DISEASE | ROME THERAPEUTICS, INC. | 2023-11-23 | — | — | US | disclosed |
| CN-110831600-B | Indole AHR inhibitors and uses thereof | 医肯纳肿瘤学公司 | 2023-10-17 | — | — | CN | disclosed |
| US-11773132-B2 | Cyclic di-nucleotides as stimulator of interferon genes modulators | BEIJING XUANYI PHARMASCIENCES CO., LTD. (CN) | 2023-10-03 | — | — | US | disclosed |
| US-11773131-B2 | Compositions and methods of modulating the immune response by activating alpha protein kinase 1 | SHANGHAI YAO YUAN BIOTECHNOLOGY CO., LTD. (CN) | 2023-10-03 | — | — | US | disclosed |
| US-11773132-B2 | Cyclic di-nucleotides as stimulator of interferon genes modulators | BEIJING XUANYI PHARMASCIENCES CO., LTD. (CN) | 2023-10-03 | — | — | US | disclosed |
| US-11773131-B2 | Compositions and methods of modulating the immune response by activating alpha protein kinase 1 | SHANGHAI YAO YUAN BIOTECHNOLOGY CO., LTD. (CN) | 2023-10-03 | — | — | US | disclosed |
| US-11766447-B2 | 3′3′-cyclic dinucleotide analogue comprising a cyclopentanyl modified nucleotide as sting modulator | INSTITUTE OF ORGANIC CHEMISTRY AND BIOCHEMISTRY ASCR, V.V.I. (CZ) | 2023-09-26 | — | — | US | disclosed |
| US-7022710-B2 | A1 adenosine receptor antagonists | CV THERAPEUTICS, INC. (US) | 2006-04-04 | — | — | US | disclosed |
| EP-1401837-B1 | PURINE DERIVATIVES AS A2B ADENOSINE RECEPTOR ANTAGONISTS | CV THERAPEUTICS INC (US) | 2005-10-19 | — | — | EP | disclosed |
| US-20050059683-A1 | A1 adenosine receptor antagonists | CV THERAPEUTICS, INC. | 2005-03-17 | — | — | US | disclosed |
| WO-2005009445-A1 | A1 ADENOSINE RECEPTOR ANTAGONISTS | CV THERAPEUTICS, INC. (US) | 2005-02-03 | — | — | WO | disclosed |
| US-20040209899-A1 | A2B adenosine receptor antagonists | PALLE VENKATA (IN) | 2004-10-21 | — | — | US | disclosed |
| US-6770651-B2 | THERAPY FOR ASTHMA, DIARRHEA | PALLE VENKATA (US) | 2004-08-03 | — | — | US | disclosed |
| EP-1401837-A1 | PURINE DERIVATIVES AS A2B ADENOSINE RECEPTOR ANTAGONISTS | CV THERAPEUTICS, INC. (US) | 2004-03-31 | — | — | EP | disclosed |
| US-20030064999-A1 | A2B adenosine receptor antagonists | PALLE VENKATA (US) | 2003-04-03 | — | — | US | disclosed |
| WO-2003006465-A1 | PARTIAL AND FULL AGONIST OF A ADENOSINE RECEPTORS | CV THERAPEUTICS, INC. (US) | 2003-01-23 | — | — | WO | disclosed |
| WO-2003002566-A1 | PURINE DERIVATIVES AS A2B ADENOSINE RECEPTOR ANTAGONISTS | CV THERAPEUTICS, INC. (US) | 2003-01-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240066047-A1 | ANTIBODY-DRUG CONJUGATES COMPRISING A CYCLIC DINUCLEOTIDE | STING1, TLR9, CGAS | CDK2 4868/4885CDK1 4739/4885CCNB1 4816/4885 |
| US-20230374058-A1 | COMPOUNDS AND METHODS FOR TREATING DISEASE | EHMT1, POLRMT, RNASE1 | CDK2 1244/4885CDK1 428/4885CCNB1 1651/4885 |
| US-11766447-B2 | 3′3′-cyclic dinucleotide analogue comprising a cyclopentanyl modified nucleotide as sting modulator | STING1, MAVS, CGAS | CDK2 4017/4885CDK1 3802/4885CCNB1 4735/4885 |
| US-20030064999-A1 | A2B adenosine receptor antagonists | ADORA2B, ADORA2A, ADORA1 | CDK2 1147/4885CDK1 3001/4885CCNB1 1310/4885 |
| US-20040209899-A1 | A2B adenosine receptor antagonists | ADORA2B, ADORA2A, ADORA1 | CDK2 1222/4885CDK1 2097/4885CCNB1 1058/4885 |
| US-11840551-B2 | Compositions and methods of modulating the immune response by activating alpha protein kinase 1 | PHKA1, PHKA2, PRKCA | CDK2 223/4885CDK1 114/4885CCNB1 634/4885 |
| US-11773132-B2 | Cyclic di-nucleotides as stimulator of interferon genes modulators | STING1, IRF3, CGAS | CDK2 3025/4885CDK1 2787/4885CCNB1 3587/4885 |
| US-11773131-B2 | Compositions and methods of modulating the immune response by activating alpha protein kinase 1 | PHKA1, PHKA2, PRKCA | CDK2 223/4885CDK1 114/4885CCNB1 634/4885 |
| US-20050059683-A1 | A1 adenosine receptor antagonists | ADORA1, ADORA2A, ADORA3 | CDK2 2905/4885CDK1 1418/4885CCNB1 1414/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.